Valeritas touts cost savings, real-world outcomes with V-Go insulin pump

In a retrospective analysis of 86 diabetic patients who switched from multiple daily insulin injections to the V-Go insulin pump, Valeritas (NSDQ:VLRX) reported this week that use of its device led to a 44% reduction in total daily insulin dose per patient.

A drastic cut to a patient’s daily insulin dose and improvement to their blood sugar levels are outcomes that Scott Abbott, director of medical development at Valeritas, has come to expect with the company’s device.

“We’ve seen this in almost every study that has been done using the V-Go insulin delivery device,” Abbott told Drug Delivery Business News.

Not only did the pump cut each patient’s daily dose and reduce blood sugar levels, it was also associated with direct pharmacy cost savings of $146.00±$378.60 per patient per month, according to data presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.

Get the full story at our sister site, Drug Delivery Business News.

The post Valeritas touts cost savings, real-world outcomes with V-Go insulin pump appeared first on MassDevice.

from MassDevice http://ift.tt/2qPhsfp